Warning: The NCBI web site requires JavaScript to function. more...
Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Kuusisto J, Andrulionyte L, Laakso M.
Curr Atheroscler Rep. 2007 Oct;9(4):274-80. Review.PMID: 18173954 [PubMed - indexed for MEDLINE]Related articles
Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M; STOP-NIDDM Study Group.
Diabetes. 2007 Apr;56(4):1181-6. Epub 2007 Feb 22.PMID: 17317762 [PubMed - indexed for MEDLINE]Related articlesFree article
Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.
Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M; STOP-NIDDM Study Group.
J Mol Med. 2006 Aug;84(8):701-8. Epub 2006 Jul 13.PMID: 16838170 [PubMed - indexed for MEDLINE]Related articles
Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Andrulionyte L, Peltola P, Chiasson JL, Laakso M; STOP-NIDDM Study Group.
Diabetes. 2006 Jul;55(7):2148-52.PMID: 16804087 [PubMed - indexed for MEDLINE]Related articlesFree article
Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.
Andrulionytè L, Zacharova J, Chiasson JL, Laakso M; STOP-NIDDM Study Group.
Diabetologia. 2004 Dec;47(12):2176-84. Epub 2004 Dec 8.PMID: 15592662 [PubMed - indexed for MEDLINE]Related articles
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on
» See more...